Japanese medical technology firm Olympus has introduced its first AI-powered clinical decision tool in collaboration with medical software company Ziosoft.
The AI application integrates advanced imaging analytics and machine learning technologies, allowing surgeons to optimise their pre-operative planning.
The initial launch includes three applications targeting liver, lung, and kidney procedures.
The tool transforms two-dimensional CT/MRI images into precise three-dimensional models, supporting lung cancer and thoracic procedure planning while reducing invasive approaches.
In liver surgery, it assists general and hepatobiliary surgeons by visualising liver anatomy, enabling liver-sparing surgeries and improving patient recovery.
The urologic surgery application supports minimally invasive nephrectomies by accurately assessing the size, location, and shape of tumours, cysts, or other abnormalities.
It is the first application in the company’s ‘Seeing the Invisible’ initiative, designed to make procedures safer, more efficient, and consistently successful.
Olympus vice president, surgical solutions business unit leader Darryl Rock said: “Olympus has a proud legacy in medical technology, particularly as a pioneer in endoscopy.
“We are excited to partner with Ziosoft, which has its own long history of developing AI software to help physicians make more accurate diagnostic and treatment decisions during procedures.
“This collaboration represents a significant step forward in Olympus’s mission to bring innovative, AI-enabled solutions to the healthcare industry.”
Unlike traditional 2D images, the new application uses CT scans and MRIs to convert static images into dynamic 3D models in real-time, using AI and thousands of radiologic images.
The AI tool aims to assist physicians in making informed clinical decisions, sparing tissue, and improving tumour margins.
The 3D procedure modelling also serves as an educational tool for surgical fellows and guides newer surgeons through unfamiliar procedures and workflows.
Olympus said the development aligns with its strategy of enhancing surgical outcomes with AI-powered clinical decision support applications.
The company is launching the surgical planning application alongside its Intelligent Endoscopy Ecosystem, which combines AI with hardware, software, services and data.
The Intelligent Endoscopy Ecosystem is designed to enhance clinical decision-making and streamline workflows in gastrointestinal procedures.
Ziosoft business development and marketing vice president Rajeev Taitriya said: “Ziosoft is committed to improving patient outcomes, and we are pleased to collaborate with Olympus to equip clinicians with greater diagnostic capabilities through advanced visualisation.
“By combining our expertise in AI-driven imaging with Olympus’ leadership in minimally invasive treatment solutions, we can help enhance surgical precision and streamline workflows, ultimately improving patient care.
“With the rise of lung cancer screening, more patients are undergoing complex segmentectomies, which Ziosoft’s REVORAS platform can support by enabling rapid pre-operative planning, allowing thoracic surgeons to make critical surgical decisions in minutes, helping to optimise outcomes and advance the standard of care.”
Recently, Olympus launched Retentia HemoClip, its new single-use haemostasis clip designed to provide 360° rotation and an intuitive one-step deployment.
